Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial

P Pfeiffer; M. Yilmaz; S. Moller; D. Zitnjak; L. Maltha; M Krogh; S Winther; L Petersen; Finn Hejlesen; K. Thomsen; C Qvortrup

doi:10.1093/annonc/mdz154.013

Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial

P Pfeiffer, M. Yilmaz, S. Moller, D. Zitnjak, L. Maltha, M Krogh, S Winther, L Petersen, Finn Hejlesen, K. Thomsen, C Qvortrup

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Artikelnummer	mdz154.013
Tidsskrift	Annals of Oncology
Vol/bind	30
Udgave nummer	Suppl. 4
Sider (fra-til)	iv130-iv131
Antal sider	2
ISSN	0923-7534
DOI	https://doi.org/10.1093/annonc/mdz154.013
Status	Udgivet - 2019
Begivenhed	ESMO World Congress on Gastrointestinal Cancer 2019 - Barcelona, Spanien Varighed: 3 jul. 2019 → 6 jul. 2019 Konferencens nummer: 21 https://www.esmo.org/Conferences/ESMO-World-GI-2019

Konference

Konference	ESMO World Congress on Gastrointestinal Cancer 2019
Nummer	21
Land/Område	Spanien
By	Barcelona
Periode	03/07/2019 → 06/07/2019
Internetadresse	https://www.esmo.org/Conferences/ESMO-World-GI-2019

Adgang til dokumentet

10.1093/annonc/mdz154.013

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Citationsformater

Pfeiffer, P., Yilmaz, M., Moller, S., Zitnjak, D., Maltha, L., Krogh, M., Winther, S., Petersen, L., Hejlesen, F., Thomsen, K., & Qvortrup, C. (2019). Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial. Annals of Oncology, 30(Suppl. 4), iv130-iv131. Artikel mdz154.013. https://doi.org/10.1093/annonc/mdz154.013

@article{27c6dfb24b19407d8475622f2dbb22c8,

title = "Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial",

author = "P Pfeiffer and M. Yilmaz and S. Moller and D. Zitnjak and L. Maltha and M Krogh and S Winther and L Petersen and Finn Hejlesen and K. Thomsen and C Qvortrup",

year = "2019",

doi = "10.1093/annonc/mdz154.013",

language = "English",

volume = "30",

pages = "iv130--iv131",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "Suppl. 4",

note = "ESMO World Congress on Gastrointestinal Cancer 2019<br/>, ESMO19 ; Conference date: 03-07-2019 Through 06-07-2019",

url = "https://www.esmo.org/Conferences/ESMO-World-GI-2019",

}

Pfeiffer, P, Yilmaz, M, Moller, S, Zitnjak, D, Maltha, L, Krogh, M, Winther, S, Petersen, L, Hejlesen, F, Thomsen, K & Qvortrup, C 2019, 'Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial', Annals of Oncology, bind 30, nr. Suppl. 4, mdz154.013, s. iv130-iv131. https://doi.org/10.1093/annonc/mdz154.013

Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial. / Pfeiffer, P; Yilmaz, M.; Moller, S. et al.
I: Annals of Oncology, Bind 30, Nr. Suppl. 4, mdz154.013, 2019, s. iv130-iv131.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer

T2 - ESMO World Congress on Gastrointestinal Cancer 2019<br/>

AU - Pfeiffer, P

AU - Yilmaz, M.

AU - Moller, S.

AU - Zitnjak, D.

AU - Maltha, L.

AU - Krogh, M

AU - Winther, S

AU - Petersen, L

AU - Hejlesen, Finn

AU - Thomsen, K.

AU - Qvortrup, C

N1 - Conference code: 21

PY - 2019

Y1 - 2019

U2 - 10.1093/annonc/mdz154.013

DO - 10.1093/annonc/mdz154.013

M3 - Conference abstract in journal

SN - 0923-7534

VL - 30

SP - iv130-iv131

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl. 4

M1 - mdz154.013

Y2 - 3 July 2019 through 6 July 2019

ER -